Across TCGA pan-cancer cohorts, EXD3 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EXD3 data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EXD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXD3 expression acts as an unfavorable survival marker.
LUAD and GBM are the cancer types where EXD3 mass-spec protein most reproducibly stratifies survival.